Cleveland Clinic Innovations

1m is a healthtech company that offers a software platform for risk management and performance improvement services.

Dyania Health focuses on enhancing clinical research efficiency through its proprietary Synapsis AI platform. This technology automates manual chart reviews, a traditionally labor-intensive process in healthcare, allowing clinicians to provide timely and effective patient care. Dyania's system is utilized by large healthcare organizations to facilitate enterprise-wide clinical trial pre-screening, conduct automated chart reviews for observational studies, and streamline complex registry reporting. By leveraging artificial intelligence and machine learning to analyze unstructured electronic medical record data, Dyania Health significantly reduces manual workloads, improves the accuracy of clinical research, and enhances the identification of potential candidates for clinical drug trials.

XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.

Strolll is a digital health startup focused on creating solutions to enhance mobility for individuals with neurological disorders. The company develops extended reality digital therapeutics that empower movement therapy through innovative approaches. Its offerings include augmented reality services designed for cueing therapy and gamified exercise, aimed at improving gait and balance while reducing the risk of falls for patients with conditions such as Parkinson's disease. By providing these therapeutic tools, Strolll enables individuals to better manage their neurological disorders and improve their overall quality of life.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Enspire DBS Therapy, Inc. is dedicated to developing a proprietary deep brain stimulation (DBS) therapy aimed at restoring motor function in stroke survivors with disabilities. Founded in 2010 and based in Cleveland, Ohio, the company is currently conducting a Phase I clinical trial to evaluate the effectiveness of its DBS therapy in stroke recovery. The therapy integrates deep brain stimulation with physical rehabilitation techniques, leveraging natural pathways to enhance the effects of both stimulation and therapy. This innovative approach aims to accelerate recovery for stroke patients, offering them improved access to rehabilitation and the potential for greater restoration of motor function.

MediView, LLC is a medical device company based in Cleveland, Ohio, established in 2017. The company specializes in developing an augmented reality surgical navigation system designed to enhance the surgical process for healthcare providers. Its primary product, MediView, utilizes extended reality technology to offer real-time, fused-holographic visualization, which aids in the ablation and biopsy of cancerous tumors. This innovative approach allows surgeons to navigate procedures with greater accuracy and efficacy compared to conventional two-dimensional displays. Additionally, MediView's technology supports remote collaboration and telehealth, providing healthcare professionals with valuable insights and the ability to examine patients more effectively using three-dimensional holograms.

Centerline Biomedical, Inc. was founded in November 2014 and is based on technology developed at the Cleveland Clinic. Centerline's mission is to develop advanced navigation systems that initially target interventional vascular procedures.

XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.

Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.

Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company based in Cleveland, Ohio, founded in 2013. The company specializes in the development and commercialization of non-invasive cancer diagnostic tests, focusing on blood-based assays for prostate, breast, and ovarian cancers, with plans to expand into lung cancer and certain neurological diseases. Cleveland Diagnostics employs proprietary solvent interaction analysis technology to investigate protein biomarkers at the structural level, enhancing the specificity and accuracy of its tests. The company has formed a strategic collaboration with Genomic Health to further its mission of improving cancer diagnostics and screening.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility. Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.

Advanced NanoTherapies, Inc. is a company that specializes in developing medical devices utilizing Sirolimus for the treatment of atherosclerosis and blockages associated with coronary and peripheral artery diseases. Founded in 2018, the company is based in Cleveland, Ohio, and focuses on a unique nanoparticle technology platform aimed at improving drug delivery for cardiovascular and endovascular applications. This innovative technology enhances medication uptake and retention within cells, providing clinicians with safer treatment options for patients suffering from peripheral artery disease. Through its advancements, Advanced NanoTherapies aims to address significant health challenges in the cardiovascular field.

Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.

Indian River Medical Center provide exceptional, patient-centered, evidence-based healthcare to residents of Indian River County and surrounding areas.

Martin Health System comprises three hospitals, one Urgent Care Center, a free-standing emergency center and numerous centers and clinics. We are dedicated to providing exceptional health care, hope and compassion to the citizens of Florida’s Treasure Coast region (which encompasses Stuart, Jensen Beach, Hobe Sound, Palm City and Port St. Lucie).

Hemex Health, Inc. specializes in developing and manufacturing medical diagnostic devices aimed at populations at risk for malaria and sickle cell disease (SCD). Founded in 2016 and based in Portland, Oregon, the company offers innovative products such as the Magneto-Optical Device (MOD), which detects all strains of malaria in under a minute, and the HemeChip, designed to identify hemoglobin disorders. Additionally, Hemex Health provides the SMART platform, facilitating early diagnosis of SCD and malaria through point-of-care testing and mobile device registries within healthcare settings. These portable diagnostic devices enable physicians, small laboratories, and field healthcare workers to deliver timely and affordable medical diagnostics, significantly improving patient care in remote areas.

Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility. Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Ascent is a national tele-health provider of certified addiction support services that uses artificial intelligence to predict impending relapse and deliver proactive coach led interventions. The service provides value add for end users by being delivered through its integrated chronic disease management platform by Sober Grid, Inc The Sober Grid app has been studied by researchers who have identified that there is a correlation with the use of the Sober Grid app and lower relapse rates. Ascent powered by Sober Grid's clients include municipal governments, insurance companies managed care organizations, drug courts, health care providers, hospitals, and treatment clinics in the United States. Ascent employs a staff of state certified addiction recovery coaches to provide on demand and scheduled sessions. Coaches are staffed 24/7/365. Coaches can be accessed via scheduled meetings or on -demand as crisis management. Available anytime, anywhere the low cost support democratizes addiction support while eliminating traditional barriers to accessing support such as access to transportation, rural settings, fear of stigma, and scheduling conflicts. All coaches are trained and certified by a state government in both addiction and mental health. Coaches adhere to the critical philosophy of multiple pathways of recovery. Coaches all have lived experience and have related real life experience and have successfully stayed in remission from acute symptoms of relapsing for a number of years.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

Explorys provides a secure cloud-computing platform specialized for the healthcare industry. We empower our customers to accelerate research and product development, while enabling critical measurement for healthcare reform, performance management and protocol safety.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

Complient Corporation, based in Cleveland, is the nation's premier provider of AED programs and actively manages hundreds of corporate and government AED programs representing more than 3,000 AED devices. Complient trains lay people to save lives and prepares them to respond to commonplace medical emergencies. To date, over 250,000 individuals have been trained on AED operation and CPR by its 150 dedicated full- and part-time trainers on staff covering all 50 states in the United States. Since its inception in 1997, over $50 million in equity venture capital has been invested to develop Complient's web-based technology infrastructure and AED program management service business. For more information, visit www.complient.com.